A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02663622

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a multicenter prospective randomized phase IIa/IIb clinical trial designed to determine the MTD (Maximum Tolerated Dose) of CD24Fc for acute GVHD (Graft Versus Host Disease) prophylaxis.

Status: 
Recruiting
Study Date: 
Mon, 02/01/2016 to Mon, 06/01/2020
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: CD24Fc Drug: Methotrexate Drug: Tacrolimus